Why licensing boards raise a competition question
Professional licensing boards have a distinctive role in state regulation. They exercise state authority, but in many states, most board members actively practice the occupation they regulate. These practitioners may help decide who can provide a service. That arrangement creates a conflict when applicants compete with the people who make licensing decisions.
The question concerns more than a board’s authority to regulate a profession. It also concerns whether a board controlled by people who participate in the relevant market receives the same antitrust immunity as the state. States generally have immunity for their own regulatory choices because federal antitrust law was not intended to override a sovereign decision to replace competition with regulation.
The Supreme Court rejected the view that a board automatically receives this protection because the state created it. State-created status alone does not provide immunity when active practitioners control decisions that may affect competitors.
The two conditions for immunity
A board controlled by market participants must meet two conditions to receive antitrust immunity for a decision that displaces competition.
First, the state must have a clearly articulated policy to displace competition. The policy must be identifiable in the state’s regulatory structure. The board’s existence, by itself, does not establish that policy.
Second, disinterested state officials must actively supervise the board’s decision. This condition is intended to make sure the decision follows state policy rather than the private interests of practitioners who sit on the board.
The two conditions assign different responsibilities to the board and the state. The board may continue to decide licensing and scope of practice questions. When market participants control the body making those decisions, however, the state must provide meaningful oversight. Immunity depends on both the policy stated by the state and the way officials review the board’s work.
What active supervision requires
Federal competition regulators later explained how active supervision should operate. The review must go beyond checking whether the board used the required procedures. A supervisor cannot establish sufficient oversight by confirming that the board held a meeting, completed the required steps, or prepared a record.
The supervisor must examine the substance of the decision. The supervising official or body must have authority to change or reject the board’s action. That authority must be genuine, and the supervisor must use it rather than approve the action automatically.
Active supervision involves review of the regulatory choice itself. The supervisor must assess what the board decided, rather than focus only on whether the board followed the formal process for reaching its decision. A review system that automatically approves every board action does not provide the substantive oversight described in competition enforcement guidance.
This framework requires states to create an oversight process that can independently evaluate board decisions. States responded by restructuring boards or adding review layers. Those changes can alter the way licensing decisions are made, the person or body with final authority, and the degree of control active practitioners retain over rules governing their occupation.
The arrangement also affects the relationship between a board and the state officials reviewing its decisions. A board may make the initial regulatory choice, while the state retains responsibility for examining that choice and deciding whether it should take effect. The review must address the decision’s substance rather than only the board’s compliance with procedural requirements.
State oversight and access across state lines
The policy issue extends beyond the internal design of licensing boards. Scope of practice rules developed by these boards determine which clinicians may prescribe and where telehealth can operate. Those rules affect who can serve patients across state lines.
A provider who serves patients in several states must account for the rules governing prescribing authority and remote care. Differences among state rules can affect provider availability and the practical options available to patients. They can also affect competition among providers by determining which professionals may offer services and the locations where they may offer them.
The antitrust framework does not decide a patient’s treatment or guarantee access to care. It helps explain why access may differ when state boards define professional boundaries and states use different arrangements for supervision. State oversight is part of the access question because review structures can influence which licensing decisions take effect and how professional services reach patients in different states. For broader context, see this overview of telemedicine regulation across states.
When states restructure boards or add review layers, they address the conditions for antitrust immunity and the way professional services reach patients across state lines. The structure of supervision can affect the authority of active practitioners, the state’s role in reviewing board decisions, and the availability of services subject to state licensing rules. The issue also appears in this discussion of an antitrust suit involving a state medical board.
For more on how providers handle these licensing and telehealth requirements, see this guide to GLP-1 clinics.